Higher levels of procoagulant microparticles in women with recurrent miscarriage are not associated with antiphospholipid antibodies

Human Reproduction

Volumn 31, Issue 1, 2016, Pages 46-52

  Martinez Zamora M A ^a   Tassies D ^b   Creus, M ^a   Reverter, J C ^b   Puerto, B ^a   Monteagudo, J ^b   Carmona, F ^a   Balasch, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Antiphosholipid antibodies; Antiphospholipid syndrome; Cell derived microparticles; Microparticles; Recurrent miscarriage; Recurrent pregnancy loss

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FEMALE; FEMALE FERTILITY; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MEMBRANE MICROPARTICLE; PROSPECTIVE STUDY; RECURRENT MISCARRIAGE; SPONTANEOUS ABORTION; THROMBOPHILIA; VENOUS BLOOD; ABORTION, HABITUAL; BLOOD; CASE CONTROL STUDY; COMPLICATION; PREGNANCY;

ABORTION, HABITUAL; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; FEMALE; HUMANS; PREGNANCY;

EID: 84957606125     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dev278     Document Type: Article

References (52)

1. Alijotas-Reig J, Garrido-Gimenez C. Current concepts and new trenes in the diagnosis and management of recurrent miscarriage. Obstet Gynecol Surv 2013;68: 445-466.
2. Alijotas-Reig J, Palacio-GarciaC, Farran-Codina I, ZarzosoC, Cabero-Roura L, Vilardell-Tarres M. Circulating cell-derived microparticles in women with pregnancy loss. Am J Reprod Immunol 2011;66: 199-208.
3. Alijotas-Reig J, Palacio-Garcia C, Llurba E, Vilardell-Tarres M. Cell-derived microparticles and vascular pregnancy complications: A systematic and comprehensive review. Fertil Steril 2013;99: 441-449.
4. Ardoin SP, Shanahan JC, Pisetsky DS. The role or microparticles in inflammation and thrombosis. Scand J Immunol 2007;66: 159-165.
5. Ay C, Freyssinet JM, Sailier T, Vormittag R, Pabinger I. Circulating procoagulant microparticles in patients with venous thromboembolism. Throb Res 2009;123: 724-726.
6. Balasch J, Carmona F, López-Soto A, Font J, Creus M, Fábregues F, IngelmoM, Vanrell JA. Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome. HumReprod 1993;8: 2234-2239.
7. Balasch J, Creus M, Fabregues F, Reverter JC, Carmona F, Tassies D, Font J, Vanrell JA. Antiphospholipid antibodies and human reproductive failure. Hum Reprod 1996;11: 2310-2315.
8. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001;85: 639-646.
9. Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, de Marchena E, Ahn YS. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003;145: 962-970.
10. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003;16: 153-168.
11. Brenner B.Haemostatic changes in pregnancy. Thromb Res 2004;114: 409-414.
12. Bretelle F, Sabtier F, Desprez D, Camoin L, Grunebaum L, Combes V, D Ercole C, Dignat-George F. Circulating microparticles: A marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 2003; 89: 486-492.
13. Buzas EI, György B, Nagy G, Falus A, Gay S. Emerging role of extracellular vesicles in inflammatory diseases. Nat Rev Rheumatol 2014;10: 356-364.
14. Carp H, Dardik R, Lubetsky A, Salomon O, Eskaraev R, Rosenthal E, Inbal A. Prevalence of circulating procoagulant microparticles in women with recurrent miscarriage: A case-controlled study. Hum Reprod 2004; 19: 191-195.
15. Christiansen OB. Epidemiology of recurrent pregnancy loss. In: Christiansen OB (ed). Recurrent Pregnancy Loss. West Sussex, UK: John Wiley & Sons Ltd., 2014, 1-13.
16. Christiansen OB, Nielsen HS, Kolte AM. Future directions of failed implantation and recurrent miscarriage research. Reprod Biomed Online 2006;13: 71-83.
17. ClarkDA. Is there anyevidence for immunologicallymediatedorimmunologically modifiable early pregnancy failure? J Assist Reprod Genet 2003;20: 63-72.
18. Clark DA, Coulam CB, Daya S, Chaouat G. Unexplained sporadic and recurrent miscarriage in the new millenium: A critical analysis of immune mechanisms and treatments. Hum Reprod Update 2001;7: 501-511.
19. Coulam CB, Clark DA, Beer AE, KuttehWH, Silver R, KwakJ, Stephenson M. Current clinical options for diagnosis and treatment of recurrent spontaneous abortion. Am J Reprod Immunol 1997;38: 57-74.
20. DavenportWB, KuttehWH. Inherited thrombophilias and adverse pregnancy outcomes: A review of screening patters and recommendations. Obstet Gynecol Clin North Am 2014;41: 133-144.
21. Daya S. Habitual abortion. In: Copeland LJ, Jarrell JJ (eds). Textbook of Gynecology, 2nd ed. Philadelphia: WB Saunders, 2000;227-271.
22. Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N, Veit V, Combes V, Gentile S, Moal V et al. Endothelial microparticles: A potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004;91: 667-673.
23. Field K, Murphy DJ. Perinatal outcomes in a subsequent pregnancy among women who have experienced recurrence miscarriage: A retrospective cohort study. Hum Reprod 2015;30: 1239-1245.
24. Freyssinet JM. Cellular microparticles: What are they bad or good for? J Thromb Haemost 2003;1: 1655-1662.
25. Galli M. Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome. Semin Thromb Hemost 2008;34: 329-334.
26. Greer IA. Endothelial cell microparticles and antiphospholipid syndrome: Pathologic explanations and diagnostic opportunities. Thromb Haemost 2004;91: 636-638.
27. Gustafson C, Shepherd AJ, Miller VM, Jayachandran M. Age and sex-specific differences in blood-borne microvesicles fromapparently healthy humans. Biol Sex Differ 2015;6: 10.
28. Hellum M, Ovstebo R, Troseid AMS, Berg JP, Brandtzaeg P, Henriksson CE. Microparticle-associated tissue factor activity measured with the Zymuphen MP-TF kit and the calibrated automated thrombogram assay. Blood Coagul Fibrinol 2012;23: 520-526.
29. JyW, Tiede M, Bidot CJ, Horstman LL, Jimenez JJ, Chirinos J, Ahn YS. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res 2007; 121: 319-325.
30. Jy W, Horstman LL, Ahn YS. Microparticle size and its relation to composition, functional activity, and clinical significance. Semin Thromb Hemost 2010;36: 876-880.
31. Kaptan K, Beyan C, Ifran A, Pekel A. Platelet-derived microparticle levels in women with recurrent spontaneous abortion. Int J Gynecol Obstet 2008; 102: 271-274.
32. Kolte AM, Bernardi LA, Christiansen OB, Quenby S, Farquharson RG, Goddijn M, Stephenson MD; on behalf of the ESHRE Special Interest Group, early pregnancy. Terminology for pregnancy loss prior to viability: A consensus statement from the ESHRE early pregnancy special interest group. Hum Reprod 2015;30: 495-498.
33. Laude I, Rangières-Bertrand C, Boyer-Neumann C, Wolf M, Mairovitz V, Hugel B, Freyssinet JM, Frydman R, Meyer D, Eschwège V. Circulating procoagulant microparticles in women with unexplained pregnancy loss: A new insight. Thromb Haemost 2001;85: 18-21.
34. Li TC, Makris M, Tomsu M, Tuckerman E, Laird S. Recurrent miscarriage: Aetiology, management and prognosis. Hum Reprod Update 2002; 8: 463-481.
35. Ludwig AK, Giebel B. Exosomes: Small vesicles participating in intercellular communication. Int J Biochem Cell Biol 2012;44: 11-15.
36. Martínez-Zamora MA, Cervera R, Balasch J. Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease. Clin Rev Allergy Immunol 2012;43: 265-274.
37. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, De Groot PG, Koike T, Meroni PL et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
38. Pasquier E, DeSaint Martin L, Bohec C, Collet M, Dignat George F, Mottier D. Unexplained pregnancy loss: A marker of basal endothelial dysfunction? Fertil Steril 2013;100: 1013-1017.
39. Patil R, Ghosh K, Satoskar P, Shetty S. Elevated procoagulant endothelial and tissue factorexpressing microparticles inwomenwith recurrent pregnancy loss. Plos One 2013;8: E81407.
40. Patil R, Ghosh K, Damania K, Bansal V, Satoskar P, Darekar A, Shetty S. Effect of anticoagulant therapy on cell-derived microparticles and pregnancy outcome in women with pregnancy loss. Br J Haematol 2015. doi: 10.1111/bjh.13460.
41. Pericleous C, Giles I, Rahman A. Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome? Lupus 2009;18: 671-675.
42. Rai R. Is miscarriage a coagulopathy? Curr Opin Obstet Gynecol 2003; 15: 265-268.
43. Saravelos SH, Regan L. Unexplained recurrent pregnancy loss. Obstet Gynecol Clin North Am 2014;41: 157-166.
44. Shahine L, Lathi R. Recurrent pregnancy loss: Evaluation and treatment. Obstet Gynecol Clin North Am 2015;42: 117-134.
45. Shapira E, Ratzon R, Shoham-Vardi I, Serjienko R, Mazor M, Bashiri A. Primary vs. secondary recurrent pregnancy loss-epidemiological characteristics, etiology, and next pregnancy outcome. J Perinat Med 2012;40: 389-396.
46. Shetty S, Patil R, Ghosh K. Role of microparticles in recurrent miscarriages and other adverse pregnancies: A review. Eur J Obstet Gynecol Reprod Biol 2013;169: 123-129.
47. Stern C, Chamley L. Antiphospholipid antibodies and coagulation defects in women with implantation failure after IVF and recurrent miscarriage. Reprod Biomed Online 2006;13: 29-37.
48. Toth B, Nieuwland R, Kern M, Rogenhofer N, Berkmans R, Rank A, Lohse P, Friese K, Thaler CJ. Systemic changes in haemostatic balance are not associated with increased levels of circulating microparticles in women with recurrent spontaneous abortion. Am J Reprod Immunol 2008; 59: 159-166.
49. Van Den Boogaard E, Cohn DM, Korevaar JC, Dawood F, Vissenberg R, Middeldorp S, Goddijn M, Farquharson RG. Number and sequence of preceding miscarriages and maternal age for the prediction of antiphospholipid syndrome in women with recurrent miscarriage. Fertil Steril 2013;99: 188-192.
50. Van Wijk MJ, Van Babel E, Surk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 2003;59: 277-287.
51. Vikerfors A, Mobarrez F, Bremme K, Holmström M, Agren A, Eelde A, Bruzelius M, Antovic A, Wallén H, Svenungsson E. Studies of microparticles in patients with the antiphospholipid syndrome (APS). Lupus 2012;21: 802-805.
52. Wenche J, Tiede M, Bidot CJ, Horstman LL, Jimenez JJ, Chirinos J, Ahn YS. Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res 2007;121: 319-325.